Sangamo Therapeutics Inc (SGMO) Expected to Announce Quarterly Sales of $26.21 Million

Equities analysts predict that Sangamo Therapeutics Inc (NASDAQ:SGMO) will announce $26.21 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Sangamo Therapeutics’ earnings, with the lowest sales estimate coming in at $22.20 million and the highest estimate coming in at $30.22 million. Sangamo Therapeutics reported sales of $21.42 million in the same quarter last year, which indicates a positive year over year growth rate of 22.4%. The firm is expected to issue its next quarterly earnings results on Wednesday, August 14th.

On average, analysts expect that Sangamo Therapeutics will report full year sales of $80.43 million for the current financial year, with estimates ranging from $50.00 million to $122.91 million. For the next year, analysts forecast that the firm will report sales of $119.10 million, with estimates ranging from $74.18 million to $241.20 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Sangamo Therapeutics.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.14). Sangamo Therapeutics had a negative return on equity of 20.75% and a negative net margin of 80.92%. The business had revenue of $8.07 million for the quarter, compared to the consensus estimate of $27.21 million.

SGMO has been the topic of a number of research analyst reports. ValuEngine downgraded shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, February 4th. Wedbush set a $10.00 price target on shares of Sangamo Therapeutics and gave the stock a “hold” rating in a report on Sunday, March 10th. BidaskClub lowered shares of Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, January 25th. Finally, Zacks Investment Research lowered shares of Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, January 18th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $15.75.

In related news, CFO Kathy Yi sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $10.00, for a total value of $50,000.00. Following the transaction, the chief financial officer now directly owns 30,512 shares in the company, valued at $305,120. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last quarter, insiders have sold 15,000 shares of company stock worth $160,550. Company insiders own 1.30% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Wasatch Advisors Inc. boosted its stake in shares of Sangamo Therapeutics by 26.8% during the first quarter. Wasatch Advisors Inc. now owns 6,437,908 shares of the biopharmaceutical company’s stock valued at $61,418,000 after purchasing an additional 1,359,170 shares during the period. BB Biotech AG bought a new position in shares of Sangamo Therapeutics during the fourth quarter valued at $15,498,000. Dimensional Fund Advisors LP increased its holdings in shares of Sangamo Therapeutics by 459.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,239,110 shares of the biopharmaceutical company’s stock valued at $14,224,000 after acquiring an additional 1,017,573 shares in the last quarter. Sphera Funds Management LTD. bought a new position in shares of Sangamo Therapeutics during the fourth quarter valued at $3,903,000. Finally, Ontario Teachers Pension Plan Board bought a new position in shares of Sangamo Therapeutics during the fourth quarter valued at $1,726,000. 54.95% of the stock is owned by institutional investors and hedge funds.

SGMO stock opened at $9.64 on Friday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.23 and a current ratio of 5.23. Sangamo Therapeutics has a 12 month low of $6.26 and a 12 month high of $19.25. The stock has a market capitalization of $1.30 billion, a price-to-earnings ratio of -13.77 and a beta of 2.89.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.

See Also: Why is the Consumer Price Index (CPI) important?

Get a free copy of the Zacks research report on Sangamo Therapeutics (SGMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.